Longevity Industry Faces Regulatory Challenges Over NMN
The Wall Street Journal reported on the booming longevity industry and the regulatory challenges faced by companies marketing NMN supplements. The article highlights the dispute between supplement companies and pharmaceutical firms over NMN’s classification and the FDA’s stance on its legality as a dietary supplement.
Federal Court Halts FDA Enforcement Against NMN
A federal court mandated the FDA to halt enforcement actions against NMN vendors and required the agency to address the NPA’s pending citizen petition. This decision provides temporary relief to NMN supplement manufacturers and consumers.
NPA Celebrates Legal Victory in NMN Case
The NPA hailed the court’s decision to stay the NMN lawsuit as a “monumental victory,” emphasizing that the FDA exceeded its authority and must adhere to the law’s provisions. The ruling allows NMN supplements to remain on the market while the FDA reviews the citizen petition.
Court Grants Joint Motion to Stay NMN Lawsuit
A federal court granted a joint motion filed by the NPA and FDA to stay proceedings in the NMN lawsuit, pending the FDA’s response to the NPA’s citizen petition. The FDA indicated it would respond to the petition by July 31, 2025, and would not prioritize enforcement actions against NMN supplements in the interim.
NPA Files Lawsuit Against FDA Over NMN Ban
The Natural Products Association (NPA) filed a lawsuit challenging the FDA’s determination that NMN is excluded from the definition of a dietary supplement due to its prior investigation as a drug. The NPA argues that the FDA’s retroactive application of the law is unlawful and harms the dietary supplement industry.
FDA Declares NMN Not a Legal Dietary Ingredient
The FDA announced that β-nicotinamide mononucleotide (β-NMN) is not a legal dietary ingredient, citing its prior investigation as a drug. The Council for Responsible Nutrition (CRN) responded, expressing concern that this decision stifles innovation and disregards consumer interests.
